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Abstract
The secretary of the US Department of Health and Human Services in February 2016 
recommended that X-linked adrenoleukodystrophy (X-ALD) be added to the recommended 
uniform screening panel for state newborn screening programs. This decision was informed by 
data presented on the accuracy of screening from New York, the only state that currently offers X-
ALD newborn screening, and published and unpublished data showing health benefits of earlier 
treatment (hematopoietic stem cell transplantation and adrenal hormone replacement therapy) for 
the childhood cerebral form of X-ALD. X-ALD newborn screening also identifies individuals with 
later-onset disease, but poor genotype–phenotype correlation makes predicting health outcomes 
difficult and might increase the risk of unnecessary treatment. Few data are available regarding the 
harms of screening and presymptomatic identification. Significant challenges exist for 
implementing comprehensive X-ALD newborn screening, including incorporation of the test, 
coordinating follow-up diagnostic and treatment care, and coordination of extended family testing 
after case identification.
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INTRODUCTION
Nearly all of the approximately 4 million newborns in the United States undergo screening 
within the first few days of life, primarily through evaluation of dried blood spots for a wide 
variety of conditions, with the goal of improving health outcomes through early detection. 
Each state determines which conditions are included in its screening program. To assist state 
newborn screening programs, the secretary of the US Department of Health and Human 
Services maintains a federally recommended uniform screening panel (RUSP), a listing of 
those conditions for which there is thought to be sufficient evidence that newborn screening 
leads to improved health outcomes compared to usual case detection and that these improved 
health outcomes outweigh the harms of screening. The secretary’s decision to add conditions 
to the RUSP is based, in part, on the recommendations from the Advisory Committee on 
Heritable Disorders in Newborns and Children (hereafter the “Advisory Committee”).
The Advisory Committee develops recommendations informed by a review of the evidence 
presented by the Condition Review Workgroup. This workgroup is external to the Advisory 
Committee and is not involved with developing or voting on the recommendations. Instead, 
the Condition Review Workgroup provides three components: a systematic evidence review 
of published reports and unpublished data; evaluation of the expected population impact of 
implementation of screening, based on modeling; and an assessment of feasibility and 
readiness of state newborn screening programs to implement newborn screening for the 
condition under consideration.
In September 2012, X-linked adrenoleukodystrophy (X-ALD) was nominated to be 
considered as an addition to the RUSP. At that time, the Advisory Committee did not find 
sufficient evidence to add X-ALD to the RUSP; therefore, a full evidence review was not 
conducted. However, by September 2014, the Advisory Committee determined that the body 
of evidence had increased, based on pilot work that had begun in New York, and therefore 
moved forward with its evaluation and recommendation process. This report by the 
Condition Review Workgroup summarizes the Advisory Committee’s recommendation 
regarding newborn screening for X-ALD and the evidence provided to the Advisory 
Committee to inform its decision. The full report provided by the Condition Review 
Workgroup and the Advisory Committee’s letter to the secretary of Health and Human 
Services is available at http://www.hrsa.gov/advisorycommittees/mchbadvisory/
heritabledisorders/nominatecondition/workgroup.html. The online report contains a 
complete description of methods and findings related to published and unpublished data.
ADVISORY COMMITTEE RECOMMENDATION
The Advisory Committee recommended in September 2015 that X-ALD be added to the 
RUSP. The Advisory Committee also recommended that federal funds be made available to 
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state newborn screening programs to assist with implementation. On 16 February 2016, the 
secretary agreed with the recommendation to add X-ALD to the RUSP. Although no new 
funding was made available for implementation, the secretary requested that federal 
agencies consider how to support state programs using existing resources.
APPROACH TO EVIDENCE REVIEW AND SYNTHESIS
The evidence review was developed to answer a series of key questions necessary to inform 
the Advisory Committee (see Table 1). A technical expert panel that included six experts in 
X-ALD screening, diagnosis, and treatment was convened to critically review the work plan 
and to provide guidance on sources of relevant evidence. These individuals were selected 
because they had expertise in screening, diagnosis, and treatment based on review of 
publications in the field. The technical expert panel did not participate in the development of 
Advisory Committee recommendations.
The primary source of evidence was based on a systematic review of published peer-
reviewed publications using several databases (MEDLINE, EMBASE, and CINAHL) from 
inception through July 2015. Articles based on human subject data published in English and 
including any study design were selected. The Condition Review Workgroup recognizes that 
there are new therapies in development (e.g., gene therapy) that were not included in the 
review because of the inability to assess benefits or harms. We also did not evaluate 
treatment with Lorenzo’s oil because of questions about its effectiveness and the emergence 
of hematopoietic stem cell transplantation (HSCT) as a treatment option. Overall, 1,314 
articles were initially included and 172 had relevant evidence for the key questions. Findings 
were supplemented with two data sets describing treatment outcomes: a single-center 
registry maintained by investigators at the Massachusetts General Hospital for Children and 
covering treatment for 30 patients from 2006 to 2015, and a multisite international registry 
maintained by BlueBird Bio (Cambridge, MA) of 59 patients with X-ALD treated with 
HSCT in 2001 or later. There was no overlap in the subjects across the two registries. The 
Condition Review Workgroup was given direct access to the data to create summary 
statistics for the Advisory Committee. However, because the owners of the databases plan 
for future separate independent publications, the Condition Review Workgroup was required 
to embargo detailed findings from the public. Although the registry data appeared complete 
and valid, the Condition Review Workgroup emphasized the small number of subjects and 
the potential for selection bias.
SUMMARY OF THE EVIDENCE
X-ALD overview
X-ALD (OMIM 300100) is a peroxisomal disorder caused by mutations in the ABCD1 
gene1 and is estimated to affect approximately 1 in 42,000 males.2 Additionally, 1 in 28,000 
females are estimated to be heterozygous for an ABCD1 mutation.2 The disorder has a broad 
phenotype and there is no genotype–phenotype correlation, even within families. Data 
extrapolated from reported incident cases suggest that the most severe form, childhood 
cerebral ALD (CCALD), affects between 31 and 57% of hemizygous males.1,3–6 CCALD 
typically presents between 2 and 10 years of age and is associated with rapid neurologic 
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decline; without treatment, death or severe disability typically occurs within approximately 3 
years.7,8 For boys who have been determined to have CCALD, treatment is HSCT 
administered at an early stage of progressive brain involvement. Because most boys with X-
ALD will not develop CCALD, and because of the risks associated with HSCT, HSCT is 
reserved for those with a clear diagnosis of CCALD in its early stages.5,7–9
Most males with CCALD will also develop adrenal insufficiency. 10,11 If unrecognized, 
delayed treatment of adrenal insufficiency can lead to death from even minor illnesses. Little 
is known about how often signs or symptoms of adrenal insufficiency lead to the diagnosis 
of X-ALD or about the timing of clinical recognition of adrenal insufficiency relative to the 
development of cerebral involvement. HSCT treatment for CCALD does not treat adrenal 
hormone insufficiency; therefore, lifelong hormone replacement therapy is required for all 
X-ALD patients with adrenal insufficiency.
Affected males with or without CCALD may develop progressive spastic paraparesis, 
sensory ataxia, and other peripheral nerve and spinal nerve involvement, collectively 
referred to as adrenomyeloneuropathy (AMN). Relatively little is known about the natural 
history of AMN. Although the literature indicates that the typical age of AMN onset is after 
age 30, the neurological symptoms may begin to manifest in later childhood or adolescence. 
Patients with AMN can develop adrenal insufficiency years or even decades before the 
disease is recognized based on the onset of neurological symptoms. The course of AMN is 
highly variable; within a mean of 13 years from recognized onset in adults, the rate of death 
or severe disability is reported to be 12%.5 Although AMN is not amenable to HSCT, 
identification and treatment of adrenal insufficiency in these patients can be lifesaving. No 
studies that characterized the morbidity associated with delayed recognition of adrenal 
insufficiency in any type of X-ALD were identified.
Heterozygous females can develop symptoms, usually of AMN, in mid- to late adulthood.12 
Although potentially serious, the impact of heterozygous females manifesting some form of 
X-ALD was not explicitly considered by the Condition Review Workgroup because of the 
adult onset of symptoms.
X-ALD newborn screening and diagnostic strategies
X-ALD is characterized by persistently elevated serum levels of particular very-long-chain 
fatty acids, and the diagnosis is confirmed by identifying ABCD1 gene mutations. Although 
ABCD1 mutations cause X-ALD, the presence of mutations does not predict disease course, 
even within families. To identify the subset of males who will develop CCALD and who 
could potentially be treated with HSCT, all males with ABCD1 mutations require ongoing 
clinical assessment, serial magnetic resonance imaging (MRI) studies of the brain, and 
assessment of adrenocortical function to guide treatment.7–9,13
Newborn screening for X-ALD is based on the elevation of a lysophosphatidylcholine 
derivative of a very-long-chain fatty acid marker in dried blood spots, abbreviated C26:0-
LPC. New York uses a two-tiered screening approach based on tandemmass spectrometry 
(MS/MS).14 The first tier uses flow-injection analysis MS/MS to measure C26:0-LPC. The 
second tier test is used for samples with elevated C26:0-LPC and relies on MS/MS coupled 
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with high-performance liquid chromatography to measure C26:0-LPC in the same dried 
blood spot. In New York, these tests are currently multiplexed with the newborn screening 
tests for Krabbe disease and Pompe disease. Newborns with elevated levels of C26:0-LPC 
on the second tier are referred for confirmatory testing. To assist in the evaluation process, 
the New York Newborn Screening Program also routinely performs Sanger sequencing to 
determine if there are mutations in the ABCD1 gene. The sequencing is generally completed 
prior to the referral. In addition to screening for X-ALD, this approach can also identify 
other peroxisomal disorders (e.g., Zellweger syndrome) often associated with death in early 
infancy and for which there is no known treatment.
Over the 18-month period ending in July 2015, approximately 365,000 newborns were 
screened for X-ALD in New York. Approximately 1.8% required the second tier test and 33 
newborns were referred for confirmatory testing. In this period, 13 males had ABCD1 
mutations identified by the New York newborn screening laboratory. Newborn screening 
identified 13 heterozygous females and one male with Klinefelter syndrome, four with 
Zellweger syndrome, one case of Aicardi-Goutieres syndrome, and one critically ill newborn 
not further characterized. Clinical experts anticipate that the infant with Klinefelter 
syndrome will have a course similar to that of the females who are heterozygous for X-ALD. 
It is not known why an infant with Aicardi-Goutieres syndrome was identified through 
newborn screening, because it is not typically associated with elevated very-long-chain fatty 
acids. The identification of these nontargeted conditions illustrates the general experience of 
newborn screening, which often picks up conditions other than those specifically targeted.
In New York, testing is offered to members of the extended family after diagnosis of X-ALD 
or identification of heterozygote females through newborn screening. No data were available 
regarding the impact of carrier testing on families or the uptake or outcomes of extended 
family testing for X-ALD.
Surveillance and treatment of X-ALD
At the time of the evidence review, it was recommended that asymptomatic males identified 
through newborn screening in New York have their adrenal function quantitatively assessed 
every 6 months and brain MRI annually from 6 months to 30 months of age, then every 6 
months from 3 to 10 years of age, and then annually again until 18 years of age.14 More 
recently, the New York newborn screening program has recommended not obtaining the first 
MRI until 12 months of age, and then annually until 3 years of age, followed by every 6 
months to 10 years of age, and then annually (J.M.K., personal communication).
In addition to supportive care, the current treatments include cortisol for individuals with 
adrenal insufficiency and HSCT for individuals with CCALD at the early stages of 
progressive brain involvement. HSCT has been reported to slow or even arrest the 
progression of leukodystrophy,15–26 but it does not modify the course of adrenal 
insufficiency or other types of myelopathy and neuropathy.
A limitation of the evidence reviewed was that no published study directly compared 
treatment outcomes for individuals detected presymptomatically (e.g., through newborn 
screening or family history) with those diagnosed symptomatically. Indirect evidence 
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suggests that earlier age of treatment with HSCT is associated with better outcomes. For 
example, more advanced disease, as indicated by increased white matter pathology found on 
brain MRI, is associated with worse outcomes following HSCT.16,22,23 Unpublished data in 
small numbers of subjects suggest that detection through family testing (i.e., 
presymptomatic identification of a young child who had a relative previously identified with 
X-ALD), compared with clinical detection resulting from testing based on signs or 
symptoms, is associated with less cerebral disease at the initiation of HSCT and also with 
longer survival and improved neurocognitive outcomes.
No data regarding the specific benefit of presymptomatic detection of adrenal insufficiency 
were identified. Cortisol for adrenal hormone insufficiency has been studied in many other 
conditions and is recognized as efficacious. However, little is known about adrenal 
insufficiency specifically associated with X-ALD, including long-term prognosis, adherence 
to cortisol treatment, or the clinical consequences of incomplete adherence.
Potential harms of X-ALD newborn screening
An important potential harm of X-ALD newborn screening is direct clinical harm related to 
treatment following early diagnosis. No recent data are available regarding the mortality risk 
associated with HSCT for X-ALD. However, among studies reporting transplant follow-up 
at 1 year or later, the overall 1-year risk of mortality following HSCT appears to be 
approximately 15% or less.15,19,21–23,27–29 The mortality rate is a function of several factors, 
including the health of the child at the time of HSCT, the type of transplantation performed, 
the degree of match between donor and recipient, and the treatment regimen used by those 
performing the HSCT. Due to lack of data, the Condition Review Workgroup was unable to 
assess the potential availability of well-matched donors if newborn screening were adopted. 
Insufficient evidence was available regarding the availability of treatment centers to offer 
HSCT, specifically for X-ALD, given the concomitant needs of having on-site clinical 
expertise in the management of X-ALD-related comorbidities and complications. In general, 
HSCT has a significant risk of mortality and morbidity. For example, a case series of 51 
infants treated with HSCT between 1992 and 2010 with long-term follow-up found an 
overall survival rate of 70% after a median follow-up of 8.9 years, and 30% had acute graft-
versus-host disease.30 Although such harms might occur in children with X-ALD regardless 
of how the condition was detected, some children who would not have undergone 
transplantation in the absence of screening might undergo HSCT. There is also the potential 
harm that individuals could receive inappropriate or ineffective treatment.
As with all newborn screening programs, there is a risk of false-positive results in an infant 
without the condition or a positive result that leads to overdiagnosis. For example, female 
heterozygotes often do not develop symptoms for decades. Although knowing the carrier 
status might inform reproductive decision making, some families might not want the 
information at birth. Individuals and families can become anxious because of the inability to 
predict phenotypic expression of the condition, which for some males might not be for 
decades.31 Because knowledge about the management of X-ALD detected 
presymptomatically is still developing, there is a risk that an individual could be treated with 
HSCT sooner than is clinically indicated and thus could face the risks of HSCT at a younger 
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age or being matched with an imperfectly matched donor when a better match might become 
available later. Delaying the first MRI to 1 year of age can help decrease the risk of 
overtreatment. Despite the broad range of potential harms, no study was included that 
specifically evaluated these harms for X-ALD newborn screening.
Projected benefits and harms of population-level screening
A limitation of the evidence reviewed was that no published study directly compared 
treatment outcomes for individuals detected presymptomatically (e.g., through newborn 
screening or family history) with those diagnosed after the development of signs or 
symptoms. Modeling was used to summarize the expected population-level impact of 
implementing newborn screening. Model inputs included published and unpublished data 
supplemented by expert input regarding the birth incidence of X-ALD, the natural history of 
X-ALD in unscreened populations, the accuracy of screening, and the impact of treatment 
stratified by the degree of cerebral involvement. It was necessary to modify the model inputs 
because of uncertainty regarding the impact of newborn screening on the observed 
epidemiology of X-ALD. Because of the limited available data, the analysis only considered 
outcomes through 15 years of age. Long-term outcome data came directly from the two 
unpublished data sets identified by the Condition Review Workgroup. Furthermore, it was 
not possible to separately consider the impact of HSCT and cortisol treatment. Based on this 
analysis, screening all 4 million newborns in the United States each year for X-ALD could 
lead to the identification of 143 (range: 64–211) newborns with a mutation in the ABCD1 
gene compared to 92 (range: 64–132) cases that would be detected through usual clinical 
care. Although the total number of cases of CCALD expected to be identified through 
newborn screening (46; range: 32–68) would be similar to the number detected through 
clinical care (46; range: 32–66), earlier detection could allow HSCT to be performed earlier 
in the disease course, thus potentially improving health outcomes. Based on incomplete 
unpublished data, by 15 years of age, no deaths would be expected in the group identified by 
screening (range: 0–21) compared to 18 deaths in the group with only clinical detection 
(range: 7–44). In those identified through newborn screening compared to those identified 
through clinical care, fewer cases of severe outcomes (e.g., patients who are nonambulatory 
and noncommunicative) would also be expected for survivors. These estimates are 
preliminary and relied on expert opinion. These results are likely to change as more data 
become available.
Newborn screening program implementation
New York currently screens for X-ALD according to the legislative mandate. Three other 
states (California, Connecticut, and New Jersey) also have a legislative mandate for X-ALD 
newborn screening, but as of the time of this writing they had not yet begun screening. A 
survey of state newborn screening programs found that most believed that the technology to 
begin screening for X-ALD could be in place within 1 to 3 years after funds were allocated. 
Newborn screening programs face the challenge of access to sufficient funds to expand 
newborn screening and the challenge of adding other recommended conditions to the panel 
(e.g., severe combined immunodeficiency).
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Several important considerations relate to follow-up after case identification. Clinical 
referral networks need to be established not only to provide diagnostic and treatment 
services but also to coordinate follow-up for individuals with presymptomatic X-ALD. 
These clinical referral networks require expertise in medical genetics, neurology, and 
endocrinology, and in the provision of HSCT for CCALD. It is important to recognize that 
HSCT is only currently recommended for those who meet criteria for CCALD at an early 
stage of progressive leukodystrophy. Therefore, each clinic providing follow-up care will 
have to be available to carefully monitor those identified by newborn screening and to be 
able to appropriately refer for HSCT, either within its network or elsewhere, when the 
criteria are met. The referral networks also have to be prepared to offer extended family 
testing after case identification through newborn screening. The Advisory Committee, based 
on its standard procedure at the time of this review, did not explicitly consider public health 
costs related to implementation of X-ALD.
The benefit of early detection compared to usual case detection was based primarily on 
unpublished data, including an analysis of proprietary registry data. Evaluating outcomes of 
screening and different approaches to diagnostic follow-up and treatment is critical to 
improving the care received by individuals identified with X-ALD through screening. Well-
designed registry data could support quality improvement activities, revision of clinical care 
guidelines, and monitoring of treatments and long-term outcomes, including neurologic 
impairment and development of adrenal insufficiency. Development of a nonproprietary 
multisite registry would allow ongoing assessment not only of the benefits of X-ALD 
newborn screening but also of the harms, which have not been the focus of previous work in 
the field. As with all rare disorders, pooling data is critical to refine approaches to diagnosis 
and treatment.
The Condition Review Workgroup identified concerns regarding the accessibility of clinical 
experts with experience in diagnosing and treating X-ALD needed to support population-
based screening of X-ALD. Access to these specialists is limited by their availability, 
geographic location, and aspects related to financing (e.g., the challenge of Medicaid 
payment across state lines). Lack of clinical expertise or limited access to care could lead to 
harm for those with a positive newborn screen, such as provision of inappropriate care.
The Condition Review Workgroup evaluated screening both males and females as is 
typically done by state newborn screening programs compared to screening males only. 
However, female heterozygotes do not develop significant symptoms in childhood. The 
routine reporting of results to families regarding children with genetic markers for adult-
onset disease is controversial,32 but it can be a strategy for identifying other cases through 
extended family testing.
Future work is needed to assess the availability of suitable matches for HSCT. Review of 
evidence was not able to provide information about the proportion of children who would 
have a match, but it noted that the use of banked umbilical cord blood could extend the pool 
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of potential matches because umbilical cord blood does not require the same degree of 
matching as donor marrow.
CONCLUSIONS
Data from New York suggest that X-ALD can be reliably identified through newborn 
screening. Not all cases of X-ALD will require treatment, but all cases of X-ALD require 
monitoring for a period of years to determine if treatment is indicated. Monitoring will 
include periodic brain MRI studies and testing of adrenal function, and it requires close 
supervision by specialists with experience in X-ALD. Although it is too early to assess 
whether screening in New York has led to improvements in health outcomes, unpublished 
evidence from other sources suggests that earlier detection of CCALD can improve survival 
and neurologic function through HSCT. In addition, screening could identify individuals 
who will develop adrenal insufficiency, which can be asymptomatic and can be treated with 
cortisol. Challenges include the poor genotype–phenotype correlation and the need to 
develop an infrastructure for both screening and follow-up care. Harms of screening include 
false-positive results, overdiagnosis, and the risks associated with HSCT performed earlier 
than needed. High-quality registry data for X-ALD could improve knowledge about 
treatments and outcomes. Such a registry could also be helpful in evaluating the impact of 
future developments (e.g., improvements in phenotype prediction, gene therapy). The 
Condition Review Workgroup did not model the costs associated with X-ALD screening. In 
the future, the Condition Review Workgroup will provide such information as a component 
of the evidence review when data can be reliably obtained.
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Table 1
Summary of key questions used in the development of the systematic evidence review
General topic Key questions
Natural history What are the natural history and epidemiology of X-ALD? What are the estimated incidence rates for the associated 




What are the direct and indirect evidence that newborn screening for X-ALD leads to improved health outcomes 
compared to usual clinical care? What is the analytic validity or clinical validity of the newborn screening approaches 
used to detect X-ALD? What diagnostic methods are available to confirm or identify the phenotypes? What methods 
are available to predict or inform the age of onset or disease severity? What harms to the individual or family are 
associated with newborn screening for X-ALD?
Treatment and long-
term follow-up
What are the standard treatments for X-ALD and evidence for their effectiveness? Do follow-up protocols that do not 
require immediate initiation of treatment exist for the management of X-ALD? What is known about the effectiveness 
of follow-up protocols in modifying health outcomes? What are the harms associated with treatments for X-ALD in 
early childhood for symptomatic or presymptomatic patients? How does this vary by phenotype? What is the impact of 
newborn screening on the public health of the population or on the public health system? What is the feasibility of 
population-based screening for X-ALD in the United States?
X-ALD, X-linked adrenoleukodystrophy.
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